Hospira slapped with FDA warning over manufacturing issues

05/31/2013 | Reuters

The FDA issued a warning letter to Hospira citing concerns regarding contamination of drugs produced at its facility in Tamil Nadu, India. The FDA discovered major quality breaches for finished medicines during an inspection in October. Sterile drug products were unprotected from contamination and the facility's surfaces weren't always sanitized before use, the FDA said. The agency is also taking a closer look at Indian drugmakers after manufacturing issues were raised against generics-makers Wockhardt and Ranbaxy Laboratories.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA